Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Theravance Biopharma ( (TBPH) ) has issued an update.
On June 5, 2025, Theravance Biopharma and Mylan entered into a Settlement Agreement with Eugia Pharma to resolve ongoing patent litigation concerning the YUPELRI® inhalation solution. The agreement allows Eugia to manufacture and market a generic version of YUPELRI® in the U.S. starting April 23, 2039, pending review by the U.S. Department of Justice and the Federal Trade Commission, while litigation continues against other ANDA filers.
The most recent analyst rating on (TBPH) stock is a Hold with a $12.00 price target. To see the full list of analyst forecasts on Theravance Biopharma stock, see the TBPH Stock Forecast page.
Spark’s Take on TBPH Stock
According to Spark, TipRanks’ AI Analyst, TBPH is a Neutral.
Theravance Biopharma’s stock score reflects a mix of financial stabilization and positive technical momentum, offset by valuation concerns due to unprofitability. The company shows potential for growth with improved cash flow and strategic advancements, but profitability and valuation issues need addressing.
To see Spark’s full report on TBPH stock, click here.
More about Theravance Biopharma
Theravance Biopharma operates in the pharmaceutical industry, focusing on the development and commercialization of respiratory medicines, including YUPELRI® (revefenacin) inhalation solution.
Average Trading Volume: 274,315
Technical Sentiment Signal: Buy
Current Market Cap: $550.5M
For detailed information about TBPH stock, go to TipRanks’ Stock Analysis page.